Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)

Completed · Phase 1

Conditions studied: Polypoidal Choroidal Vasculopathy

In brief

This is a 12 month study of monthly injections of ranibizumab in subjects with polypoidal choroidal vasculopathy as diagnosed by fluoresceins/indocyanine green (FA/ICG) angiography.

Key facts

Study ID

NCT00424710

Run by

Hawaii Pacific Health

People needed

17

Starts

2007-01-01

Expected to finish

2010-09-01

Last updated by the study team

2014-11-05

Who can join

Age: 25 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Ability to provide informed consent and comply with study assessment for the duration of one year
• Age >= 25 years
• Polypoidal Choroidal Vasculopathy as noted on fluorescein and ICG angiography: active leakage, active bleeding or recent decrease in vision
• BCVA using ETDRS 20/32 to 20/400

You may not qualify if…

• Any history of previous vitrectomy
• Previous cataract or ocular surgery within 2 months of day 0
• Active intraocular inflammation in the study eye
• Active infections conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
• Participation with another investigational drug within the past 30 days
• Prior sodium pegaptanib, verteporfin photodynamic therapy, intravitreal steroids, or bevacizumab within 30 days of study entry
• Blood pressure >180/110 (use of antihypertensives is allowed as long as hypertension can be controlled and is stable)
• Pregnancy

Where it is running

• Retina Consultants of Hawaii — Honolulu, Hawaii, United States
• The Retina Center at Pali Momi — ‘Aiea, Hawaii, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.